Indocyanine Green
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Indocyanine Green
- Generic name
- INDOCYANINE GREEN AND WATER
- Manufacturer
- Renew Pharmaceuticals Limited
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- a6f24787-c243-445a-9c55-7c7479b292d9
- SPL ID
- 3abdfd10-c4e6-472e-b4eb-d4953f029132
- Version
- 9
- Effective date
- 2025-04-13
- Source export date
- 2026-09-28
- Source partition
- 13
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0013-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/e78bf8aa9f90ab13e640d254dfbd4fe5bfeca4995ec5f9d51bce3356e249cab7/drug-label-0013-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 06:37:17
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 040811 | derived:openfda.application_number |
| application number | ANDA040811 | openfda.application_number | |
| brand name | Indocyanine Green | openfda.brand_name | |
| generic name | INDOCYANINE GREEN AND WATER | openfda.generic_name | |
| manufacturer name | Renew Pharmaceuticals Limited | openfda.manufacturer_name | |
| ndc | package | 70100-424-02 | openfda.package_ndc |
| ndc | package | 0409-4887-17 | openfda.package_ndc |
| ndc | product | 70100-424 | openfda.product_ndc |
| ndc11 | package | 70100042402 | derived:openfda.package_ndc |
| ndc11 | package | 00409488717 | derived:openfda.package_ndc |
| spl id | 3abdfd10-c4e6-472e-b4eb-d4953f029132 | id | |
| spl set id | a6f24787-c243-445a-9c55-7c7479b292d9 | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions: Hypersensitivity reactions including anaphylaxis and urticaria have occurred. Always have cardiopulmonary resuscitation personnel and equipment readily available and monitor patients. ( 5.1 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions including anaphylaxis, urticaria and deaths due to anaphylaxis have been reported following intravenous administration of Indocyanine Green [see Adverse Reactions ( 6 )]. Indocyanine Green is contraindicated in patients with a history of hypersensitivity to indocyanine green [see Contraindications ( 4 )] . Always have cardiopulmonary resuscitation personnel and equipment readily available and monitor all patients for hypersensitivity reactions. 5.2 Interference with Thyroid Radioactive Iodine Uptake Studies Because Indocyanine Green contains sodium iodide, the iodine-binding capacity of thyroid tissue may be reduced for at least one week following administration [see Drug Interactions ( 7 )].
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: • Hypersensitivity Reactions [see Warnings and Precautions ( 5.1 )] . The following adverse reactions have been identified during post-approval use of Indocyanine Green. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Immune System Disorders : Anaphylaxis, urticaria The most common adverse reactions reported are anaphylaxis and urticaria. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Diagnostic Green LLC at 1-844-424-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.